https://www.biopharmawatch.com/news/ALGN/align-technology-extel-2026-rankings BiopharmaWatch en 2026-11-06T17:59:00.000Z Align Technology Recognized in Extel’s 2026 All-America Executive Team Rankings https://www.biopharmawatch.com/news/GILD/lenacapavir-hiv-prevention-trial-results BiopharmaWatch en 2026-11-06T17:16:00.000Z New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-phase-1-2a-study-melanoma BiopharmaWatch en 2026-11-06T17:00:00.000Z Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 https://www.biopharmawatch.com/news/IMCR/immunocore-phase-1-2-trial-brenetafusp-kimmtrak BiopharmaWatch en 2026-11-06T17:00:00.000Z Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma https://www.biopharmawatch.com/news/CHE/chemed-quarterly-dividend-announcement BiopharmaWatch en 2026-11-06T16:23:00.000Z Chemed Corporation Declares Quarterly Dividend of 70 Cents https://www.biopharmawatch.com/news/HCWB/hcw-biologics-hcw11-040-sitc-presentation BiopharmaWatch en 2026-11-06T16:00:00.000Z HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer https://www.biopharmawatch.com/news/EVAX/evax-01-phase-2-trial-results BiopharmaWatch en 2026-11-06T16:00:00.000Z New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01 https://www.biopharmawatch.com/news/INCY/2026-ingenuity-awards-gvhd-recipients BiopharmaWatch en 2026-11-06T15:40:00.000Z 2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute https://www.biopharmawatch.com/news/OSRH/osr-health-exercises-15-million-vxm01-equity-option BiopharmaWatch en 2026-11-06T15:11:00.000Z OSR Health Exercises $15 Million VXM01 Equity Option, Elects Settlement Through Staged Convertible Notes https://www.biopharmawatch.com/news/HALO/halozyme-reaffirms-projects-zero-minimal-impact-royalty-revenue-through-least BiopharmaWatch en 2026-11-06T15:04:00.000Z Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029 https://www.biopharmawatch.com/news/QGEN/qiagen-shareholders-approve-jonathan-pratt BiopharmaWatch en 2026-11-06T15:00:00.000Z QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director https://www.biopharmawatch.com/news/HALO/fda-approves-rybrevant-faspro-halozyme-advanced-cancer BiopharmaWatch en 2026-11-06T14:57:00.000Z U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer https://www.biopharmawatch.com/news/INKT/mink-therapeutics-sitc-2026-data-inkt-therapy BiopharmaWatch en 2026-11-06T14:48:00.000Z MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026) https://www.biopharmawatch.com/news/HCWB/hcw-biologics-t-cell-engager-sitc-2026 BiopharmaWatch en 2026-11-06T14:15:00.000Z HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting https://www.biopharmawatch.com/news/ALGN/align-technology-270-million-stock-repurchase BiopharmaWatch en 2026-11-06T14:10:00.000Z Align Technology Announces $270 Million Accelerated Stock Repurchase Agreement https://www.biopharmawatch.com/news/OBX/obsidian-therapeutics-amsoki-cel-sitc-2026 BiopharmaWatch en 2026-11-06T14:05:00.000Z Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/IMRX/atebimetinib-combinations-ratios-cancer-models-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:37.000Z Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026 https://www.biopharmawatch.com/news/AGEN/agenus-bot-bal-treatment-survival-mcrc-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:00.000Z Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026 https://www.biopharmawatch.com/news/CADL/candel-therapeutics-sitc-2026-data BiopharmaWatch en 2026-11-06T14:00:00.000Z Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-ctx-10726-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:00.000Z Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/IMCR/immunocore-q3-2026-financial-results-update BiopharmaWatch en 2026-11-06T14:00:00.000Z Immunocore reports third quarter financial results and provides a business update https://www.biopharmawatch.com/news/NERV/minerva-neurosciences-q3-2026-results BiopharmaWatch en 2026-11-06T14:00:00.000Z Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/BCTX/briacell-bria-pro-positive-preclinical-data-sitc-2026 BiopharmaWatch en 2026-11-06T14:00:00.000Z BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026 https://www.biopharmawatch.com/news/IMNN/imnn-001-activates-t-cell-immunity-advanced-ovarian-cancer BiopharmaWatch en 2026-11-06T14:00:00.000Z IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer https://www.biopharmawatch.com/news/ONMD/onemednet-q3-2026-revenue-outlook BiopharmaWatch en 2026-11-06T13:30:00.000Z OneMedNet Reports Preliminary Revenue for Third Quarter 2026 and Fourth Quarter 2026 Outlook https://www.biopharmawatch.com/news/BCDA/biocardia-completes-pmda-consultation-cardiamp-approval BiopharmaWatch en 2026-11-06T13:30:00.000Z BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-netherton-now-video BiopharmaWatch en 2026-11-06T13:30:00.000Z Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-06T13:30:00.000Z CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 https://www.biopharmawatch.com/news/ICUI/icu-medical-presentation-jefferies-conference-2026 BiopharmaWatch en 2026-11-06T13:30:00.000Z ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/CGON/cg-oncology-reports-q3-2026-results BiopharmaWatch en 2026-11-06T13:15:00.000Z CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/ACRV/acrivon-expands-immunology-inflammation-acquisition-phase-2-ready-differentiated-oral BiopharmaWatch en 2026-11-06T13:00:30.000Z Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB https://www.biopharmawatch.com/news/ACRV/acrivon-acquires-acr-525-jak1-inhibitor BiopharmaWatch en 2026-11-06T13:00:30.000Z Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB https://www.biopharmawatch.com/news/ASND/transcon-cnp-market-exclusivity-eu-approval BiopharmaWatch en 2026-11-06T13:00:00.000Z Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union https://www.biopharmawatch.com/news/ENGN/engene-participate-upcoming-investor-conferences-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z enGene to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-reports-inducement-awards-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-nasdaq-listing-rule-5635-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MDXG/mimedx-participate-upcoming-investor-conferences-20261106 BiopharmaWatch en 2026-11-06T13:00:00.000Z MIMEDX to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-reports-business-progress-q3-2026 BiopharmaWatch en 2026-11-06T13:00:00.000Z Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TARA/protara-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-06T13:00:00.000Z Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/IART/integra-lifesciences-2026-ubs-global-healthcare-conference BiopharmaWatch en 2026-11-06T13:00:00.000Z Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference https://www.biopharmawatch.com/news/NHC/nhc-reports-third-quarter-2026-earnings BiopharmaWatch en 2026-11-06T12:30:00.000Z NHC Reports Third Quarter 2026 Earnings https://www.biopharmawatch.com/news/SNGX/soligenix-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T12:30:00.000Z Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EHC/encompass-health-sea-pines-hospital-closure BiopharmaWatch en 2026-11-06T12:30:00.000Z Encompass Health announces indefinite closure of Sea Pines Rehabilitation Hospital due to flood damage https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-surgeon-guided-autonomy-intelligent-surgery BiopharmaWatch en 2026-11-06T12:30:00.000Z Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery https://www.biopharmawatch.com/news/DAVI/davion-healthcare-appoints-vienna-capital-partners BiopharmaWatch en 2026-11-06T12:30:00.000Z Davion Healthcare Plc Appoints Vienna Capital Partners to Support US$100 Million Acquisition Financing Strategy https://www.biopharmawatch.com/news/IFRX/inflarx-phase-1-data-izicopan-safety-profile BiopharmaWatch en 2026-11-06T12:30:00.000Z InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T12:30:00.000Z Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CANF/can-fite-pursue-global-licensing-strategic-partnerships-bio-europe-2026 BiopharmaWatch en 2026-11-06T12:23:00.000Z Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones https://www.biopharmawatch.com/news/CANF/can-fite-global-licensing-bio-europe-2026 BiopharmaWatch en 2026-11-06T12:23:00.000Z Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones https://www.biopharmawatch.com/news/NEO/neogenomics-participate-investor-conferences BiopharmaWatch en 2026-11-06T12:05:00.000Z NeoGenomics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/HLF/herbalife-participate-stephens-investment-conference BiopharmaWatch en 2026-11-06T12:05:00.000Z Herbalife to Participate in 1 on 1 Meetings at Stephens Annual Investment Conference on November 19 https://www.biopharmawatch.com/news/ANIK/anika-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T12:05:00.000Z Anika Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TMCI/treace-medical-concepts-q3-2026-results BiopharmaWatch en 2026-11-06T12:05:00.000Z Treace Medical Concepts Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TMCI/treace-tailorplasty-surgical-cases BiopharmaWatch en 2026-11-06T12:04:00.000Z Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor’s Bunion Correction System https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-precise-btn-results-ata-meeting BiopharmaWatch en 2026-11-06T12:00:00.000Z Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting https://www.biopharmawatch.com/news/BHC/bausch-health-salix-liver-meeting-2026 BiopharmaWatch en 2026-11-06T12:00:00.000Z Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026 https://www.biopharmawatch.com/news/EYPT/eyepoint-participation-investor-conferences-scientific-meetings BiopharmaWatch en 2026-11-06T12:00:00.000Z EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261106 BiopharmaWatch en 2026-11-06T12:00:00.000Z Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KRRO/korro-presents-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-06T12:00:00.000Z Korro to Present at the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/GUTS/fractyl-health-q3-2026-financial-results BiopharmaWatch en 2026-11-06T12:00:00.000Z Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026 https://www.biopharmawatch.com/news/MSLE/satellos-changes-efficacy-endpoint-basecamp-trial BiopharmaWatch en 2026-11-06T12:00:00.000Z Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback https://www.biopharmawatch.com/news/LLY/lilly-hims-hers-expand-access-fda-approved-medicines BiopharmaWatch en 2026-11-06T11:47:00.000Z Lilly and Hims & Hers expand access to FDA-approved Lilly medicines https://www.biopharmawatch.com/news/MRNA/moderna-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-06T11:45:00.000Z Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/VOGX/vogenx-reports-q3-2026-results-and-highlights BiopharmaWatch en 2026-11-06T11:30:00.000Z Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-q3-2026-results BiopharmaWatch en 2026-11-06T11:27:00.000Z Elanco Animal Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/ELAN/elanco-pet-health-consumer-research-october-2026 BiopharmaWatch en 2026-11-06T11:27:00.000Z October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-06T10:50:00.000Z Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/RARE/ultragenyx-maa-ux111-review-mhra BiopharmaWatch en 2026-11-06T08:30:00.000Z Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) https://www.biopharmawatch.com/news/MOLN/molecular-partners-preclinical-data-mp0632-sitc-2026 BiopharmaWatch en 2026-11-06T06:00:08.000Z Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026 https://www.biopharmawatch.com/news/PHAR/mhra-approves-pharming-joenja-treatment-children-apds BiopharmaWatch en 2026-11-06T06:00:00.000Z MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. https://www.biopharmawatch.com/news/INO/inovio-pricing-75-million-public-offering BiopharmaWatch en 2026-11-06T04:18:00.000Z INOVIO Announces Pricing of Approximately $75 Million Public Offering https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-public-offering-pricing BiopharmaWatch en 2026-11-06T03:42:00.000Z Orchestra BioMed Announces Pricing of Public Offering https://www.biopharmawatch.com/news/JNJ/fda-approval-rybrevant-faspro-head-neck-cancer BiopharmaWatch en 2026-11-06T02:03:00.000Z Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-bamzireotide-trial-data-nanets-2026 BiopharmaWatch en 2026-11-06T01:10:00.000Z Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs https://www.biopharmawatch.com/news/NHC/nhc-announces-common-dividend-20261106 BiopharmaWatch en 2026-11-06T01:00:00.000Z NHC Announces Common Dividend https://www.biopharmawatch.com/news/REVB/revelation-biosciences-financial-results-september-2026 BiopharmaWatch en 2026-11-05T22:29:00.000Z Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-third-quarter-earnings BiopharmaWatch en 2026-11-05T22:23:00.000Z CORRECTING and REPLACING Nu Skin Enterprises Reports Third Quarter Earnings https://www.biopharmawatch.com/news/COO/coopercompanies-release-date-fourth-quarter-full-year-2026 BiopharmaWatch en 2026-11-05T22:23:00.000Z CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2026 https://www.biopharmawatch.com/news/MRNA/moderna-mrna-influenza-covid-vaccines-authorization BiopharmaWatch en 2026-11-05T22:20:00.000Z Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-share-repurchase BiopharmaWatch en 2026-11-05T22:15:00.000Z Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases https://www.biopharmawatch.com/news/CTKB/cytek-aurora-evo-award-drug-discovery-innovation BiopharmaWatch en 2026-11-05T22:00:30.000Z Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-announces-quarterly-dividend-20261105 BiopharmaWatch en 2026-11-05T22:00:00.000Z Thermo Fisher Scientific Announces Quarterly Dividend https://www.biopharmawatch.com/news/CODX/co-diagnostics-q3-2026-earnings-release BiopharmaWatch en 2026-11-05T22:00:00.000Z Co-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and Webcast https://www.biopharmawatch.com/news/BDSX/biodesix-third-quarter-2026-results-highlights BiopharmaWatch en 2026-11-05T21:46:26.538Z Biodesix Announces Third Quarter 2026 Results and Highlights https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:46:00.465Z vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/CRIS/curis-q3-2026-results-conference-call BiopharmaWatch en 2026-11-05T21:38:00.000Z Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026 https://www.biopharmawatch.com/news/NKTX/nkarta-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:34:00.000Z Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MSLE/satellos-investor-call-update-clinical-strategy BiopharmaWatch en 2026-11-05T21:32:00.000Z Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study https://www.biopharmawatch.com/news/MTD/mettler-toledo-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:30:00.000Z Mettler-Toledo International Inc. Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/CMPS/compass-pathways-announces-new-employee-inducement-grants-nasdaq-listing-rule-20261105 BiopharmaWatch en 2026-11-05T21:30:00.000Z Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CON/concentra-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:30:00.000Z Concentra Announces Results For Its Third Quarter Ended September 30, 2026 and Raises FY 2026 Guidance https://www.biopharmawatch.com/news/BIOA/bioage-labs-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:30:00.000Z BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/TARS/tarsus-participate-upcoming-investor-conferences-20261105 BiopharmaWatch en 2026-11-05T21:30:00.000Z Tarsus to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ELUT/elutia-reports-q3-2026-results-nxt-41x-fda-submission BiopharmaWatch en 2026-11-05T21:17:00.000Z Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch https://www.biopharmawatch.com/news/ULS/uls-solutions-modernize-life-science-training BiopharmaWatch en 2026-11-05T21:15:00.000Z UL Solutions Collaborates on Cross-Industry Initiative to Modernize Life Science Regulated Training https://www.biopharmawatch.com/news/AMN/amn-healthcare-q3-2026-results BiopharmaWatch en 2026-11-05T21:15:00.000Z AMN HEALTHCARE ANNOUNCES THIRD QUARTER 2026 RESULTS https://www.biopharmawatch.com/news/CTMX/cytomx-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:15:00.000Z CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/SI/shoulder-innovations-reports-third-quarter-2026-financial-results-raises-full BiopharmaWatch en 2026-11-05T21:11:00.000Z Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook https://www.biopharmawatch.com/news/ACET/adicet-bio-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:10:00.000Z Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:10:00.000Z Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 https://www.biopharmawatch.com/news/NEPH/nephros-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:10:00.000Z Nephros Announces Strong Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-new-ceo-jeannette-bankes BiopharmaWatch en 2026-11-05T21:08:00.000Z Tandem Diabetes Care Names Jeannette Bankes as President and Chief Executive Officer https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:07:00.000Z Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-q3-2026-results-ph-762-update BiopharmaWatch en 2026-11-05T21:06:36.000Z Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation https://www.biopharmawatch.com/news/NTRA/natera-announces-leadership-transition BiopharmaWatch en 2026-11-05T21:06:00.000Z Natera Announces Leadership Transition https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-q3-earnings BiopharmaWatch en 2026-11-05T21:06:00.000Z Nu Skin Enterprises Reports Third Quarter Earnings https://www.biopharmawatch.com/news/STLN/starling-oncology-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:06:00.000Z Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-q3-results-2026 BiopharmaWatch en 2026-11-05T21:05:58.000Z AVITA Medical Reports Third Quarter Results https://www.biopharmawatch.com/news/DH/definitive-healthcare-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:58.000Z Definitive Healthcare Reports Financial Results for Third Quarter 2026 https://www.biopharmawatch.com/news/CVRX/cvrx-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:54.000Z CVRx Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/CAMP/camp4-reports-q3-2026-results-and-highlights BiopharmaWatch en 2026-11-05T21:05:53.000Z CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:51.000Z Caribou Biosciences Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/APMD/apnimed-inc-reports-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-11-05T21:05:51.000Z Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/FOCL/focaltherics-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:50.000Z FocalTherics™ Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PROF/profound-medical-q3-2026-results-distribution-expansion BiopharmaWatch en 2026-11-05T21:05:00.000Z Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth https://www.biopharmawatch.com/news/IRTC/irhythm-holdings-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z iRhythm Holdings Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RNXT/renovorx-reports-record-q3-2026-revenue BiopharmaWatch en 2026-11-05T21:05:00.000Z RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million https://www.biopharmawatch.com/news/ABCL/abcellera-presentation-ubs-global-biopharma-conference-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026 https://www.biopharmawatch.com/news/ALEC/alector-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Alector Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PTGX/protagonist-reports-q3-2026-results-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/FLGT/fulgent-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Fulgent Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Puma Biotechnology Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PRTA/prothena-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Prothena Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Tandem Diabetes Care Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GH/guardant-health-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-11-05T21:05:00.000Z Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NTRA/natera-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Natera Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-announces-quarterly-dividend-20261105 BiopharmaWatch en 2026-11-05T21:05:00.000Z Nu Skin Enterprises Announces Quarterly Dividend https://www.biopharmawatch.com/news/INGN/inogen-announces-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Inogen Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-q3-2026-results-autonomous-lab-sale BiopharmaWatch en 2026-11-05T21:05:00.000Z Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Guardian Pharmacy Services Reports Third Quarter 2026 Financial Results; Raises Full-Year Guidance https://www.biopharmawatch.com/news/ASTH/astrana-health-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Astrana Health, Inc. Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/SOLV/solventum-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Solventum Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TXG/10x-genomics-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z 10x Genomics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Castle Biosciences Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/CYRX/cryoport-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Cryoport Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HALO/halozyme-reports-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:05:00.000Z HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-05T21:05:00.000Z Tyra Biosciences to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AORT/artivion-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Artivion Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NUTX/nutex-health-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z NUTEX HEALTH REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/SGHT/sight-sciences-investor-conferences-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Sight Sciences to Present at Two Upcoming Investor Conferences https://www.biopharmawatch.com/news/EQ/equillium-participate-investor-conferences BiopharmaWatch en 2026-11-05T21:05:00.000Z Equillium to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-inducement-grant-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-11-05T21:05:00.000Z Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MDWD/mediwound-closes-17-25-million-offering BiopharmaWatch en 2026-11-05T21:05:00.000Z MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/RZLT/rezolute-q1-fiscal-2027-results-business-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ICUI/icu-medical-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:05:00.000Z ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range https://www.biopharmawatch.com/news/SANA/sana-biotechnology-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Nyxoah Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/MOBI/mobia-medical-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Mobia Medical Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MGNX/macrogenics-participate-investor-conferences-november BiopharmaWatch en 2026-11-05T21:05:00.000Z MacroGenics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-guggenheim-healthcare-conference-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-nomlabofusp-icar-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-positive-data-liver-meeting-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026 https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:03:47.000Z Health Catalyst Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/SINT/sintx-reports-third-quarter-2026-revenue-growth BiopharmaWatch en 2026-11-05T21:02:29.000Z SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-jefferies-conference-2026 BiopharmaWatch en 2026-11-05T21:02:27.000Z Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference https://www.biopharmawatch.com/news/KROS/keros-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T21:02:08.000Z Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SPRY/ars-pharma-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:02:01.000Z ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-05T21:02:00.000Z Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/JANX/janux-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T21:02:00.000Z Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TMDX/transmedics-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-05T21:02:00.000Z TransMedics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OMDA/omada-health-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:02:00.000Z Omada Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/GMED/globus-medical-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:02:00.000Z Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-results-corporate-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Celldex Reports Third Quarter Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ACH/accendra-health-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Accendra Health Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q3-2026-results-pipeline-progress BiopharmaWatch en 2026-11-05T21:01:00.000Z Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress https://www.biopharmawatch.com/news/NGNE/neurogene-announces-inducement-grant-nasdaq-listing-rule-5635-c-4 BiopharmaWatch en 2026-11-05T21:01:00.000Z Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates https://www.biopharmawatch.com/news/INO/inovio-proposed-public-offering-common-stock BiopharmaWatch en 2026-11-05T21:01:00.000Z INOVIO Announces Proposed Public Offering of its Common Stock https://www.biopharmawatch.com/news/RIGL/rigel-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Rigel Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-et-700-pilot-study-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability https://www.biopharmawatch.com/news/ATYR/atyr-pharma-third-quarter-2026-results-update BiopharmaWatch en 2026-11-05T21:01:00.000Z aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update https://www.biopharmawatch.com/news/VYGR/voyager-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Voyager Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/MNKD/mannkind-q3-2026-financial-results-business-update BiopharmaWatch en 2026-11-05T21:01:00.000Z MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-public-offering BiopharmaWatch en 2026-11-05T21:01:00.000Z Orchestra BioMed Announces Proposed Public Offering https://www.biopharmawatch.com/news/CELC/celcuity-reports-q3-2026-results-and-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261105 BiopharmaWatch en 2026-11-05T21:01:00.000Z Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q3-2026 BiopharmaWatch en 2026-11-05T21:01:00.000Z Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/INAB/in8bio-reports-q3-2026-results-and-highlights BiopharmaWatch en 2026-11-05T21:01:00.000Z IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/VERA/vera-therapeutics-business-update-q3-2026 BiopharmaWatch en 2026-11-05T21:01:00.000Z Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Dentsply Sirona Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/ASND/ascendis-report-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 https://www.biopharmawatch.com/news/INGN/inogen-announces-leadership-transition BiopharmaWatch en 2026-11-05T21:00:00.000Z Inogen Announces Leadership Transition https://www.biopharmawatch.com/news/INMB/inmune-bio-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:00:00.000Z INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update https://www.biopharmawatch.com/news/TLSA/tiziana-host-investor-call-inform-ms-results BiopharmaWatch en 2026-11-05T19:00:00.000Z Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results https://www.biopharmawatch.com/news/GMAB/genmab-financial-results-nine-months-2026 BiopharmaWatch en 2026-11-05T16:02:00.000Z Genmab Announces Financial Results for the Nine Months of 2026 https://www.biopharmawatch.com/news/BIIB/biogen-update-private-payer-coverage-zurzuvae BiopharmaWatch en 2026-11-05T16:00:00.000Z Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone) https://www.biopharmawatch.com/news/IGC/igc-pharma-alzheimers-agitation-drug-patented BiopharmaWatch en 2026-11-05T15:18:00.000Z IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears https://www.biopharmawatch.com/news/NVO/novo-nordisk-share-trading-disclosure BiopharmaWatch en 2026-11-05T15:02:00.000Z Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons https://www.biopharmawatch.com/news/MDGL/madrigal-rezdiffra-real-world-data-aasld-2026 BiopharmaWatch en 2026-11-05T15:00:00.000Z Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra https://www.biopharmawatch.com/news/ALT/altimmune-reclaim-phase-2-trial-pemvidutide-aasld-2026 BiopharmaWatch en 2026-11-05T15:00:00.000Z Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/VIR/vir-biotechnology-eclipse-1-data-presentation BiopharmaWatch en 2026-11-05T15:00:00.000Z Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call https://www.biopharmawatch.com/news/GILD/gilead-phase-3-ideal-study-results-livdelzi BiopharmaWatch en 2026-11-05T15:00:00.000Z Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC) https://www.biopharmawatch.com/news/VSEE/vsee-health-new-hospital-agreements BiopharmaWatch en 2026-11-05T14:30:00.000Z VSee Health Announces 13 New Hospital Agreements Expected to Generate More Than $3 Million in Annual Revenue https://www.biopharmawatch.com/news/MMSI/merit-medical-avf-cohort-wrap-global-registry BiopharmaWatch en 2026-11-05T14:25:00.000Z Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry https://www.biopharmawatch.com/news/KAPA/kairos-pharma-biotech-breakthrough-award-oncology BiopharmaWatch en 2026-11-05T14:15:00.000Z Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-ras-targeted-therapies BiopharmaWatch en 2026-11-05T14:13:00.000Z AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer https://www.biopharmawatch.com/news/SNWV/sanuwave-health-comments-2027-medicare-rate-ultramist BiopharmaWatch en 2026-11-05T14:08:00.000Z Sanuwave Health Comments on 2027 Medicare Physician Fee Schedule Rate for Ultramist https://www.biopharmawatch.com/news/NTHI/neonc-reports-q3-2026-results-and-clinical-progress BiopharmaWatch en 2026-11-05T14:00:16.000Z NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress https://www.biopharmawatch.com/news/AMGN/repatha-lowers-heart-attack-risk-study BiopharmaWatch en 2026-11-05T14:00:00.000Z REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY https://www.biopharmawatch.com/news/HIMS/hims-hers-benefits-new-partners-health-support BiopharmaWatch en 2026-11-05T14:00:00.000Z Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most https://www.biopharmawatch.com/news/SBC/shonan-beauty-clinic-newsweek-medical-tourism-2027 BiopharmaWatch en 2026-11-05T14:00:00.000Z Shonan Beauty Clinic Named to Newsweek’s “World’s Best Hospitals & Clinics for Medical Tourism 2027” https://www.biopharmawatch.com/news/ZLAB/zai-lab-zocilurtatug-pelitecan-update BiopharmaWatch en 2026-11-05T14:00:00.000Z Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas https://www.biopharmawatch.com/news/CODX/co-diagnostics-participate-global-tuberculosis-events BiopharmaWatch en 2026-11-05T14:00:00.000Z Co-Diagnostics to Participate in Three Global Tuberculosis Events in November as CoSara Advances Toward Anticipated India Launch https://www.biopharmawatch.com/news/POCI/precision-optics-2-million-follow-on-order BiopharmaWatch en 2026-11-05T14:00:00.000Z Precision Optics Announces $2 Million Follow-On Order from Existing Top-Tier Aerospace Customer https://www.biopharmawatch.com/news/IVF/invo-fertility-patientfi-affordable-treatment BiopharmaWatch en 2026-11-05T14:00:00.000Z INVO Fertility Partners with PatientFi to Help Make Fertility Treatment More Affordable https://www.biopharmawatch.com/news/MTVA/metavia-da-1726-phase-1-results BiopharmaWatch en 2026-11-05T13:55:00.000Z MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-05T13:45:00.000Z DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026 https://www.biopharmawatch.com/news/HCWB/hcw-biologics-secures-debt-financing BiopharmaWatch en 2026-11-05T13:45:00.000Z HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing https://www.biopharmawatch.com/news/PRE/care-bears-prenetics-global-partnership BiopharmaWatch en 2026-11-05T13:32:00.000Z Care Bears And Prenetics' IM8 Announce Global Partnership https://www.biopharmawatch.com/news/AIDX/vote-2020-biolabs-special-meeting-december-2026 BiopharmaWatch en 2026-11-05T13:31:00.000Z REMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026 https://www.biopharmawatch.com/news/PRE/prenetics-authentic-brands-care-bears-partnership BiopharmaWatch en 2026-11-05T13:30:37.000Z Prenetics’ IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-tome-skincare-launch-media-coverage BiopharmaWatch en 2026-11-05T13:30:00.000Z Dermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial Launch https://www.biopharmawatch.com/news/APVO/aptevos-mipletamig-reduces-infusion-reactions-aml BiopharmaWatch en 2026-11-05T13:30:00.000Z Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML https://www.biopharmawatch.com/news/QTI/qt-imaging-presents-canaccord-genuity-forum BiopharmaWatch en 2026-11-05T13:30:00.000Z QT Imaging to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum https://www.biopharmawatch.com/news/MIRM/genedx-mirum-sponsored-testing-programs BiopharmaWatch en 2026-11-05T13:30:00.000Z GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing https://www.biopharmawatch.com/news/TMO/thermo-fisher-introduces-value-priced-qpcr-master-mixes BiopharmaWatch en 2026-11-05T13:30:00.000Z Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance https://www.biopharmawatch.com/news/FBLG/fibrobiologics-european-patent-fibroblast-delivery BiopharmaWatch en 2026-11-05T13:30:00.000Z FibroBiologics Announces Grant of European Patent for Fibroblast Delivery of Tumor Inhibitory Agents https://www.biopharmawatch.com/news/NBIX/neurocrine-ingrezza-survey-results-tardive-dyskinesia BiopharmaWatch en 2026-11-05T13:30:00.000Z Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules https://www.biopharmawatch.com/news/LSTA/marea-therapeutics-upcoming-investor-conferences BiopharmaWatch en 2026-11-05T13:30:00.000Z Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences https://www.biopharmawatch.com/news/MBOT/microbot-medical-ip-portfolio-expansion BiopharmaWatch en 2026-11-05T13:30:00.000Z Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-reports-third-quarter-2026-financial BiopharmaWatch en 2026-11-05T13:30:00.000Z Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IRON/disc-medicine-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T13:30:00.000Z Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T13:30:00.000Z Dogwood Therapeutics Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DERM/journey-medical-q3-2026-financial-results-announcement BiopharmaWatch en 2026-11-05T13:30:00.000Z Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/EYE/americas-best-flagship-store-alpharetta BiopharmaWatch en 2026-11-05T13:27:00.000Z America's Best Opens Flagship Store Built Around One Connected Experience https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-best-place-to-work-2026 BiopharmaWatch en 2026-11-05T13:25:00.000Z Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year https://www.biopharmawatch.com/news/SCYX/scynexis-reports-q3-2026-results-and-update BiopharmaWatch en 2026-11-05T13:20:00.000Z SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ANVS/annovis-pricing-21-million-public-offering BiopharmaWatch en 2026-11-05T13:05:00.000Z Annovis Announces Pricing of $21.0 Million Public Offering https://www.biopharmawatch.com/news/RTSN/retension-pharmaceuticals-guggenheim-conference-2026 BiopharmaWatch en 2026-11-05T13:02:00.000Z Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/LABT/lakewood-amedex-redemption-series-c-preferred-stock BiopharmaWatch en 2026-11-05T13:02:00.000Z Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption https://www.biopharmawatch.com/news/ARQT/arcutis-phase-3-study-zoryve-atopic-dermatitis BiopharmaWatch en 2026-11-05T13:00:24.000Z Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis https://www.biopharmawatch.com/news/ARQT/arcutis-phase-3-study-zoryve-cream-atopic-dermatitis BiopharmaWatch en 2026-11-05T13:00:24.000Z Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis https://www.biopharmawatch.com/news/OSTX/os-therapies-phase-2b-herlystic-drug-substance-requalification BiopharmaWatch en 2026-11-05T13:00:00.000Z OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-investor-conferences-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Processa Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ALT/altimmune-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-05T13:00:00.000Z Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 https://www.biopharmawatch.com/news/COSM/cosmos-health-cosmo-farm-automated-infrastructure BiopharmaWatch en 2026-11-05T13:00:00.000Z Cosmos Health's CosmoFarm Begins Commissioning New Automated Order-Processing and Vehicle-Loading Infrastructure, Advancing Capacity That Could Support Over $120 Million in Annual Revenue https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-q3-2026-report BiopharmaWatch en 2026-11-05T13:00:00.000Z Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 https://www.biopharmawatch.com/news/OGN/organon-vtama-analysis-acaa-meeting-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting https://www.biopharmawatch.com/news/ICLR/icon-firecrest-ai-video-engine-launch BiopharmaWatch en 2026-11-05T13:00:00.000Z ICON Launches FIRECREST AI-Directed Video Engine, Changing the Economics of Site Communications https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-gx-03-award-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Turn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-fda-phase-3-edg-7500-hcm BiopharmaWatch en 2026-11-05T13:00:00.000Z Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring https://www.biopharmawatch.com/news/MMED/minimed-participate-upcoming-investor-conferences-20261105 BiopharmaWatch en 2026-11-05T13:00:00.000Z MiniMed to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/SCNI/scinai-reports-revenue-growth-cdmo-expansion BiopharmaWatch en 2026-11-05T13:00:00.000Z Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands https://www.biopharmawatch.com/news/NVAX/novavax-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T13:00:00.000Z Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/LPCN/lipocine-financial-results-q3-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Lipocine Announces Financial Results for the Third Quarter of 2026 https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-belapectin-aasld-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026 https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-05T13:00:00.000Z Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T13:00:00.000Z Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/ECOR/electrocore-participate-canaccord-genuity-medtech-diagnostics-digital-health-services BiopharmaWatch en 2026-11-05T13:00:00.000Z electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-investor-conferences-november BiopharmaWatch en 2026-11-05T13:00:00.000Z Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/IMMP/immutep-poster-presentations-ctos-esmo-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026 https://www.biopharmawatch.com/news/BDMD/baird-medical-alpmed-fda-ce-submissions-ire-system BiopharmaWatch en 2026-11-05T13:00:00.000Z Baird Medical and Alpmed Announce FDA 510(k) and EU CE Submissions for Irreversible Electroporation (IRE) System https://www.biopharmawatch.com/news/STTK/shattuck-labs-q3-2026-results-business-highlights BiopharmaWatch en 2026-11-05T13:00:00.000Z Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/SCTX/scribe-therapeutics-participate-upcoming-healthcare-investor-conferences BiopharmaWatch en 2026-11-05T13:00:00.000Z Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-q3-2026-results-update BiopharmaWatch en 2026-11-05T13:00:00.000Z Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Ovid Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/SGP/spyglass-pharma-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-05T13:00:00.000Z SpyGlass Pharma to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-q3-2026-results-conference-call BiopharmaWatch en 2026-11-05T13:00:00.000Z Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12 https://www.biopharmawatch.com/news/SLDB/solid-biosciences-guggenheim-healthcare-conference BiopharmaWatch en 2026-11-05T13:00:00.000Z Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/SGHT/cms-establishes-supply-code-tearcare-smartlids BiopharmaWatch en 2026-11-05T13:00:00.000Z Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids https://www.biopharmawatch.com/news/BLTE/belite-bio-webcast-november-2026-financial-results BiopharmaWatch en 2026-11-05T13:00:00.000Z Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-november-2026-events BiopharmaWatch en 2026-11-05T13:00:00.000Z Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026 https://www.biopharmawatch.com/news/VCEL/vericel-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:55:00.000Z Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-05T12:45:00.000Z Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/RCEL/avitamedical-medicare-payment-framework-recell-2027 BiopharmaWatch en 2026-11-05T12:45:00.000Z AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027 https://www.biopharmawatch.com/news/SABS/sab-bio-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:30:49.000Z SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/AGL/agilon-health-virtual-investor-event-november-2026 BiopharmaWatch en 2026-11-05T12:30:00.000Z agilon health to Host Virtual Investor Event “Driving Performance At Scale: The agilon Framework” on November 17, 2026 https://www.biopharmawatch.com/news/AGEN/agenus-reports-q3-2026-results-bot-bal-marketing-authorizations BiopharmaWatch en 2026-11-05T12:30:00.000Z Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-q3-2026-results BiopharmaWatch en 2026-11-05T12:30:00.000Z Sonida Senior Living Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/BHVN/biohaven-graves-disease-research-phase-3-trial-bhv-1300 BiopharmaWatch en 2026-11-05T12:30:00.000Z Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-05T12:30:00.000Z Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/LFMD/life-md-expands-access-lilly-glp-1-medicines BiopharmaWatch en 2026-11-05T12:30:00.000Z LifeMD expands access to Lilly’s self-pay GLP-1 medicines, enabling option to dispense and ship directly to patients nationwide https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:30:00.000Z Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/CRON/cronos-group-reports-q3-2026-results BiopharmaWatch en 2026-11-05T12:30:00.000Z Cronos Group Reports 2026 Third Quarter Results https://www.biopharmawatch.com/news/MDCX/medicus-pharma-present-bio-europe-2026 BiopharmaWatch en 2026-11-05T12:30:00.000Z Medicus Pharma to Present at BIO-Europe 2026 https://www.biopharmawatch.com/news/COLL/collegium-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:30:00.000Z Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance https://www.biopharmawatch.com/news/CABA/cabaletta-bio-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T12:30:00.000Z Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LNTH/lantheus-welcomes-cms-cy27-final-rule-advancing-access-diagnostic-radiopharmaceuticals BiopharmaWatch en 2026-11-05T12:15:00.000Z Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals https://www.biopharmawatch.com/news/LNTH/lantheus-cms-cy27-final-rule-diagnostic-radiopharmaceuticals BiopharmaWatch en 2026-11-05T12:15:00.000Z Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals https://www.biopharmawatch.com/news/DTIL/precision-biosciences-pricing-offering-common-stock BiopharmaWatch en 2026-11-05T12:10:00.000Z Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:10:00.000Z Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/ACB/aurora-cannabis-fiscal-2027-q2-results BiopharmaWatch en 2026-11-05T12:05:00.000Z Aurora Cannabis Announces Fiscal 2027 Second Quarter Results https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-raises-2026-guidance BiopharmaWatch en 2026-11-05T12:05:00.000Z Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-q3-2026-results BiopharmaWatch en 2026-11-05T12:05:00.000Z REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/SEER/seer-victory-itc-patent-dispute-nanomics BiopharmaWatch en 2026-11-05T12:00:37.000Z Seer Secures Key Victory in ITC Patent Dispute as Investigative Staff Backs All Requested Remedies Against Nanomics https://www.biopharmawatch.com/news/KRSA/korsana-biosciences-q3-2026-results-update BiopharmaWatch en 2026-11-05T12:00:33.000Z Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-q3-2026-results-micvo-progress BiopharmaWatch en 2026-11-05T12:00:30.000Z Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO) https://www.biopharmawatch.com/news/COCH/envoy-medical-q3-2026-results-progress BiopharmaWatch en 2026-11-05T12:00:00.000Z Envoy Medical Reports Third Quarter 2026 Results and Highlights Continued Progress https://www.biopharmawatch.com/news/GANX/gain-therapeutics-late-breakers-poster-presentations BiopharmaWatch en 2026-11-05T12:00:00.000Z Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences https://www.biopharmawatch.com/news/AKBA/akebia-vocal-trial-positive-results-vadadustat BiopharmaWatch en 2026-11-05T12:00:00.000Z Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/XERS/xeris-biopharma-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/DTIL/precision-biosciences-positive-dsmb-review-pbgene-dmd BiopharmaWatch en 2026-11-05T12:00:00.000Z Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study https://www.biopharmawatch.com/news/DTIL/precision-biosciences-pbgene-hbv-data-aasld-2026 BiopharmaWatch en 2026-11-05T12:00:00.000Z Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure https://www.biopharmawatch.com/news/ALKS/alkermes-research-neuroscience-education-institute-fall-congress BiopharmaWatch en 2026-11-05T12:00:00.000Z Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress https://www.biopharmawatch.com/news/ZTS/zoetis-third-quarter-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance https://www.biopharmawatch.com/news/NTRA/signatera-monitoring-immunotherapy-ctdna-clearance-survival BiopharmaWatch en 2026-11-05T12:00:00.000Z Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers https://www.biopharmawatch.com/news/EVH/evolent-announces-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Evolent Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/GNPX/genprex-reqorsa-gene-therapy-aging-resilience BiopharmaWatch en 2026-11-05T12:00:00.000Z Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress https://www.biopharmawatch.com/news/EVGN/evogene-q3-2026-financial-results-release BiopharmaWatch en 2026-11-05T12:00:00.000Z Evogene Schedules Third Quarter 2026 Financial Results Release https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-acaa-meeting-2026 BiopharmaWatch en 2026-11-05T12:00:00.000Z Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-bexobrutideg-phase-1a-1b-trial-data BiopharmaWatch en 2026-11-05T12:00:00.000Z Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition https://www.biopharmawatch.com/news/APYX/apyx-medical-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Apyx Medical Corporation Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KRRO/korro-reports-q3-2026-results-and-update BiopharmaWatch en 2026-11-05T12:00:00.000Z Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T12:00:00.000Z Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/LNTH/lantheus-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Lantheus Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q3-2026-revenue-report BiopharmaWatch en 2026-11-05T12:00:00.000Z Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates https://www.biopharmawatch.com/news/IMDX/imdx-third-quarter-results-november-2026 BiopharmaWatch en 2026-11-05T12:00:00.000Z iMDx to Release Third Quarter Results on November 16, 2026 https://www.biopharmawatch.com/news/AVTX/avalotherapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T12:00:00.000Z Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/EYPT/eyepoint-report-q3-2026-results-november-12 BiopharmaWatch en 2026-11-05T12:00:00.000Z EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/CLYM/climb-bio-q3-2026-financial-results-updates BiopharmaWatch en 2026-11-05T12:00:00.000Z Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-q3-2026-results-updates BiopharmaWatch en 2026-11-05T12:00:00.000Z Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates https://www.biopharmawatch.com/news/OKYO/okyo-pharma-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-05T12:00:00.000Z OKYO Pharma to Present at the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-05T12:00:00.000Z Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/FATE/fate-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/MCTA/charming-medical-nasdaq-delisting-notice BiopharmaWatch en 2026-11-05T12:00:00.000Z Charming Medical Limited Announces Receipt of Nasdaq Delisting Determination Notice. https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Entrada Therapeutics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/PMN/promis-neurosciences-november-conferences-2026 BiopharmaWatch en 2026-11-05T12:00:00.000Z ProMIS Neurosciences to Participate in Upcoming Conferences in November https://www.biopharmawatch.com/news/IRD/opus-genetics-phase-1-2-trial-opgx-best1 BiopharmaWatch en 2026-11-05T12:00:00.000Z Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-drug-discovery-award-2026 BiopharmaWatch en 2026-11-05T12:00:00.000Z Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards https://www.biopharmawatch.com/news/VTRS/viatris-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-05T11:59:00.000Z Viatris Reports Third-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-05T11:59:00.000Z Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-05T11:51:00.000Z ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LTGO/latigo-biotherapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T11:47:00.000Z Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/LLY/lilly-showcase-new-retatrutide-taltz-ixekizumab-zepbound-tirzepatide-data-acr BiopharmaWatch en 2026-11-05T11:45:00.000Z Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity https://www.biopharmawatch.com/news/LLY/lilly-retatrutide-taltz-zepbound-acr-convergence-2026 BiopharmaWatch en 2026-11-05T11:45:00.000Z Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity https://www.biopharmawatch.com/news/WRBY/warby-parker-q3-2026-results BiopharmaWatch en 2026-11-05T11:45:00.000Z Warby Parker Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-20261105 BiopharmaWatch en 2026-11-05T11:45:00.000Z Teleflex Announces Quarterly Dividend https://www.biopharmawatch.com/news/CAH/cardinal-health-q1-fy2027-results-outlook BiopharmaWatch en 2026-11-05T11:45:00.000Z Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook https://www.biopharmawatch.com/news/LTGO/latigo-biotherapeutics-ceo-transition-growth BiopharmaWatch en 2026-11-05T11:45:00.000Z Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth https://www.biopharmawatch.com/news/BDX/bd-reports-fourth-quarter-fiscal-2026-results BiopharmaWatch en 2026-11-05T11:30:00.000Z BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results https://www.biopharmawatch.com/news/EVMN/evommune-webcast-evo570-immunology-portfolio BiopharmaWatch en 2026-11-05T11:30:00.000Z Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET https://www.biopharmawatch.com/news/TFX/teleflex-third-quarter-results-2026 BiopharmaWatch en 2026-11-05T11:30:00.000Z Teleflex Reports Third Quarter Financial Results and Full Year 2026 Outlook https://www.biopharmawatch.com/news/ZLAB/zai-lab-q3-2026-financial-results BiopharmaWatch en 2026-11-05T11:30:00.000Z Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates https://www.biopharmawatch.com/news/INFU/infusystem-financial-results-q3-2026 BiopharmaWatch en 2026-11-05T11:30:00.000Z InfuSystem Announces Financial Results for Third Quarter 2026 https://www.biopharmawatch.com/news/HSIC/henry-schein-investor-conferences-november-december BiopharmaWatch en 2026-11-05T11:30:00.000Z Henry Schein to Participate in Upcoming Investor Conferences in November and December https://www.biopharmawatch.com/news/AGIO/agios-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T11:30:00.000Z Agios Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/BDX/bdx-dividend-increase-share-repurchase-2026 BiopharmaWatch en 2026-11-05T11:25:00.000Z BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases https://www.biopharmawatch.com/news/TRLV/trulieve-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-05T11:15:00.000Z Trulieve Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/RDY/dr-reddys-generic-semaglutide-brazil-approval BiopharmaWatch en 2026-11-05T11:06:07.000Z Dr. Reddy’s receives marketing authorization for generic semaglutide injection in Brazil https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2027-second-quarter-results BiopharmaWatch en 2026-11-05T11:00:00.000Z Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results https://www.biopharmawatch.com/news/ONC/beone-medicines-q3-2026-financial-results BiopharmaWatch en 2026-11-05T11:00:00.000Z BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/OSCR/oscar-health-q3-2026-results-outlook BiopharmaWatch en 2026-11-05T11:00:00.000Z Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full Year 2026 Outlook https://www.biopharmawatch.com/news/HAE/haemonetics-q2-fiscal-2027-results BiopharmaWatch en 2026-11-05T11:00:00.000Z Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website https://www.biopharmawatch.com/news/LFST/lifestance-reports-strong-q3-2026-results BiopharmaWatch en 2026-11-05T11:00:00.000Z LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T11:00:00.000Z Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update https://www.biopharmawatch.com/news/PRVA/privia-health-reports-strong-q3-2026-results BiopharmaWatch en 2026-11-05T11:00:00.000Z Privia Health Reports Strong Third Quarter and Year-to-Date 2026 Results https://www.biopharmawatch.com/news/ENOV/enovis-third-quarter-2026-results BiopharmaWatch en 2026-11-05T11:00:00.000Z ENOVIS Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/VCRE/vicore-pharma-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T07:20:00.000Z Vicore Pharma Announces Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/EVO/evotec-q3-2026-results-growth-momentum BiopharmaWatch en 2026-11-05T07:18:00.000Z Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-acquires-egetis-therapeutics BiopharmaWatch en 2026-11-05T06:33:00.000Z ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business https://www.biopharmawatch.com/news/MOLN/molecular-partners-present-mp0712-2026-conferences BiopharmaWatch en 2026-11-05T06:00:28.000Z Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026 https://www.biopharmawatch.com/news/IPHA/innate-pharma-q3-2026-update BiopharmaWatch en 2026-11-05T05:00:00.000Z Innate Pharma Reports Third Quarter 2026 Business and Financial Update https://www.biopharmawatch.com/news/MESO/ryoncil-first-line-treatment-pediatric-gvhd BiopharmaWatch en 2026-11-05T00:11:00.000Z Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar https://www.biopharmawatch.com/news/ABT/abbott-novo-partnership-launch-plosbrio-semaglutide BiopharmaWatch en 2026-11-05T00:00:00.000Z Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific https://www.biopharmawatch.com/news/HCM/hutchmed-sovleplenib-fda-orphan-drug-designation-aiha BiopharmaWatch en 2026-11-05T00:00:00.000Z HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-ash-2026-presentation-data BiopharmaWatch en 2026-11-04T23:30:00.000Z Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026 https://www.biopharmawatch.com/news/IMRN/immuron-revenue-growth-report-november-2026 BiopharmaWatch en 2026-11-04T23:10:00.000Z Emerging Growth Research Reports Continued Revenue Growth at Immuron https://www.biopharmawatch.com/news/ALNY/alnylam-1-billion-share-repurchase-leadership-change BiopharmaWatch en 2026-11-04T22:15:00.000Z Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership https://www.biopharmawatch.com/news/EVMN/evommune-announces-30-million-private-placement BiopharmaWatch en 2026-11-04T22:10:00.000Z Evommune Announces $30 Million Private Placement https://www.biopharmawatch.com/blog/biotech-anatomy-2026 BiopharmaWatch en 2026-11-04T22:06:48.952Z Biotech Anatomy 2026: What 1,640 Readouts Really Paid https://www.biopharmawatch.com/news/EVMN/evommune-license-evo570-hinova-pharmaceuticals BiopharmaWatch en 2026-11-04T22:02:00.000Z Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals https://www.biopharmawatch.com/news/VMD/viemed-healthcare-q3-2026-financial-results BiopharmaWatch en 2026-11-04T22:00:00.000Z Viemed Healthcare Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-inducement-awards-nasdaq-listing-rule-5635-c-20261104 BiopharmaWatch en 2026-11-04T22:00:00.000Z Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/INM/inmed-announces-results-2026-annual-meeting BiopharmaWatch en 2026-11-04T21:51:00.000Z InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T21:36:00.000Z Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 https://www.biopharmawatch.com/news/NHC/national-healthcare-properties-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:35:00.000Z National Healthcare Properties Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/FOCL/focaltherics-investor-conferences-2026 BiopharmaWatch en 2026-11-04T21:30:49.000Z FocalTherics™ to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/FOCL/focaltherics-participate-investor-conferences BiopharmaWatch en 2026-11-04T21:30:49.000Z FocalTherics™ to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ACRV/acrivon-presents-eortc-nci-aacr-symposium-2026 BiopharmaWatch en 2026-11-04T21:30:39.000Z Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics https://www.biopharmawatch.com/news/ACRV/acrivon-presentation-eortc-nci-aacr-symposium-2026 BiopharmaWatch en 2026-11-04T21:30:39.000Z Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics https://www.biopharmawatch.com/news/MSA/msa-safety-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T21:30:00.000Z MSA Safety to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-nasdaq-listing-rule-5635-c-4 BiopharmaWatch en 2026-11-04T21:30:00.000Z Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/STE/steris-fiscal-2027-q2-financial-results BiopharmaWatch en 2026-11-04T21:30:00.000Z STERIS Announces Financial Results for Fiscal 2027 Second Quarter https://www.biopharmawatch.com/news/EDSA/edesa-biotech-guggenheim-healthcare-conference-2026 BiopharmaWatch en 2026-11-04T21:30:00.000Z Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-2026-jefferies-conference BiopharmaWatch en 2026-11-04T21:30:00.000Z Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/OPK/opko-health-q3-2026-results BiopharmaWatch en 2026-11-04T21:23:00.000Z OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-reports-q1-results BiopharmaWatch en 2026-11-04T21:22:00.000Z Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance https://www.biopharmawatch.com/news/ARAY/accuray-reverse-stock-split-november-2026 BiopharmaWatch en 2026-11-04T21:20:00.000Z Accuray Announces 1-for-40 Reverse Stock Split https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-q3-2026-financial-results-update BiopharmaWatch en 2026-11-04T21:15:36.000Z X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/CDRE/cadre-holdings-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:15:00.000Z Cadre Holdings Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EW/edwards-lifesciences-q3-results-2026 BiopharmaWatch en 2026-11-04T21:15:00.000Z Edwards Lifesciences Reports Third Quarter Results https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:15:00.000Z Bio-Rad Reports Third-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARDT/ardent-health-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:15:00.000Z Ardent Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/EHTH/ehealth-announces-q3-2026-results BiopharmaWatch en 2026-11-04T21:15:00.000Z eHealth, Inc. Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/MMED/minimed-fiscal-year-2027-q2-results BiopharmaWatch en 2026-11-04T21:15:00.000Z MiniMed to Announce Its Fiscal Year 2027 Second Quarter Financial Results https://www.biopharmawatch.com/news/MDT/medtronic-q2-fiscal-year-2027-results BiopharmaWatch en 2026-11-04T21:15:00.000Z Medtronic to announce financial results for its second quarter of fiscal year 2027 https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-nasdaq-listing-rule-5635-c-20261104 BiopharmaWatch en 2026-11-04T21:15:00.000Z Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BTMD/biote-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:11:00.000Z Biote Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MCK/mckesson-fiscal-2027-q2-results-guidance BiopharmaWatch en 2026-11-04T21:10:00.000Z McKesson Reports Fiscal 2027 Second Quarter Results and Raises Full Year Adjusted EPS Guidance https://www.biopharmawatch.com/news/ANVS/annovis-launch-public-offering BiopharmaWatch en 2026-11-04T21:07:00.000Z Annovis Announces Launch of Proposed Public Offering https://www.biopharmawatch.com/news/SLDB/solid-biosciences-q3-2026-results-business-updates BiopharmaWatch en 2026-11-04T21:07:00.000Z Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T21:06:00.000Z Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/AGMB/agomab-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T21:05:47.000Z Agomab to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:46.000Z Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:42.000Z PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance https://www.biopharmawatch.com/news/VCYT/veracyte-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:37.000Z Veracyte Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NATR/natures-sunshine-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Nature's Sunshine Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EOLS/evolus-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook https://www.biopharmawatch.com/news/QGEN/qiagen-reports-full-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z QIAGEN Reports Full Q3 2026 Results https://www.biopharmawatch.com/news/KRMD/koru-medical-investor-conference-participation BiopharmaWatch en 2026-11-04T21:05:00.000Z KORU Medical Systems to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AHCO/adapthealth-participate-ubs-conference BiopharmaWatch en 2026-11-04T21:05:00.000Z AdaptHealth Corp. to Participate in Upcoming Investor Conference https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-q3-2026-results-financial-guidance BiopharmaWatch en 2026-11-04T21:05:00.000Z Acadia Healthcare Announces Third Quarter 2026 Results and Raises Full Year 2026 Financial Guidance https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-bio-thrax-supply-order BiopharmaWatch en 2026-11-04T21:05:00.000Z Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War https://www.biopharmawatch.com/news/VIR/vir-biotechnology-corporate-update-q3-2026 BiopharmaWatch en 2026-11-04T21:05:00.000Z Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AGL/agilon-health-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z agilon health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/SDGR/schrodinger-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Schrödinger Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/INVA/innoviva-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-q3-2026-results-pipeline-update BiopharmaWatch en 2026-11-04T21:05:00.000Z Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update https://www.biopharmawatch.com/news/ARAY/accuray-fiscal-2027-first-quarter-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Accuray Reports Fiscal 2027 First Quarter Financial Results https://www.biopharmawatch.com/news/PGEN/precigen-reports-q3-2026-results-papzimeos-revenue-growth BiopharmaWatch en 2026-11-04T21:05:00.000Z Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance https://www.biopharmawatch.com/news/SERA/sera-prognostics-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/NVST/envista-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Envista Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/CAI/caris-life-sciences-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance https://www.biopharmawatch.com/news/NUVB/nuvation-bio-q3-2026-financial-results-update BiopharmaWatch en 2026-11-04T21:05:00.000Z Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z LeMaitre Q3 2026 Financial Results https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-third-quarter-2026-financial-results-raises-full BiopharmaWatch en 2026-11-04T21:05:00.000Z Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives https://www.biopharmawatch.com/news/PACB/pacbio-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z PacBio Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-q3-2026-results-and-update BiopharmaWatch en 2026-11-04T21:05:00.000Z Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CLOV/clover-health-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Clover Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-guggenheim-conference-2026 BiopharmaWatch en 2026-11-04T21:05:00.000Z Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates https://www.biopharmawatch.com/news/MDCX/medicus-pharma-q3-2026-update-call BiopharmaWatch en 2026-11-04T21:05:00.000Z Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026 https://www.biopharmawatch.com/news/BLLN/billiontoone-reports-q3-2026-results-guidance BiopharmaWatch en 2026-11-04T21:05:00.000Z BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-third-quarter-2026-financial-results-provides-business BiopharmaWatch en 2026-11-04T21:05:00.000Z ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q3-2026-results-call BiopharmaWatch en 2026-11-04T21:05:00.000Z Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/PNTG/pennant-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Pennant Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-q3-2026-results-business-highlights BiopharmaWatch en 2026-11-04T21:05:00.000Z OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/ECOR/electrocore-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z electroCore Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grant-nasdaq-listing-rule-5635-c-20261104 BiopharmaWatch en 2026-11-04T21:05:00.000Z Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026 https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-04T21:05:00.000Z Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/IMRX/immuneering-presents-guggenheim-healthcare-innovation-conference BiopharmaWatch en 2026-11-04T21:05:00.000Z Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Cytek Biosciences Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-investor-conferences-2026 BiopharmaWatch en 2026-11-04T21:05:00.000Z Alamar Biosciences to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/KLRA/kailera-reports-q3-2026-results-business-updates BiopharmaWatch en 2026-11-04T21:05:00.000Z Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:02:47.000Z Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:02:00.000Z Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BDMD/baird-medical-statement-share-price-volatility BiopharmaWatch en 2026-11-04T21:02:00.000Z Baird Medical Issues Statement Regarding Recent Share Price Volatility https://www.biopharmawatch.com/news/GRAL/grail-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:02:00.000Z GRAIL Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TKNO/teknova-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-04T21:01:49.000Z Teknova Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TKNO/teknova-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:01:49.000Z Teknova Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:01:00.000Z STAAR Surgical Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/PSNL/personalis-reports-third-quarter-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Personalis Reports Third Quarter Results https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-q3-2026-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Maravai LifeSciences Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/XNCR/xencor-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Xencor Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMCC/im-cannabis-raises-us1200000-convertible-note-financing BiopharmaWatch en 2026-11-04T21:01:00.000Z IM Cannabis Raises US$1,200,000 of Gross Proceeds in Convertible Note Financing https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Edgewise Therapeutics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OLMA/olema-oncology-presents-combination-data-sabcs-2026 BiopharmaWatch en 2026-11-04T21:01:00.000Z Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium https://www.biopharmawatch.com/news/ARVN/arvinas-arv-393-ash-2026-presentation BiopharmaWatch en 2026-11-04T21:01:00.000Z Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting https://www.biopharmawatch.com/news/BDMD/baird-medical-nasdaq-notification-minimum-bid-price BiopharmaWatch en 2026-11-04T21:01:00.000Z Baird Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-11-04T21:01:00.000Z Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CLDX/celldex-investor-conferences-november-december-2026 BiopharmaWatch en 2026-11-04T21:01:00.000Z Celldex to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/DSGN/design-therapeutics-q3-2026-results-updates BiopharmaWatch en 2026-11-04T21:01:00.000Z Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-nasdaq-listing-rule-20261104 BiopharmaWatch en 2026-11-04T21:01:00.000Z Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/OM/outset-medical-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Outset Medical Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results https://www.biopharmawatch.com/news/BCRX/biocryst-present-investor-conferences BiopharmaWatch en 2026-11-04T21:01:00.000Z BioCryst to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261104 BiopharmaWatch en 2026-11-04T21:01:00.000Z Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-04T21:00:00.000Z AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/VRTX/vertex-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T21:00:00.000Z Vertex to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ARQT/arcutis-q3-2026-financial-results-update BiopharmaWatch en 2026-11-04T21:00:00.000Z Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CYTK/cytokinetics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-04T21:00:00.000Z Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-quality-of-life-data-eortc-cltg-2026 BiopharmaWatch en 2026-11-04T18:45:00.000Z Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe